TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$288 Million

SpringWorks Therapeutics, Inc.

Follow-on Offering

Bookrunner, October 2020

SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics is a late-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as a number of other programs addressing highly prevalent, genetically-defined cancers. The Company is focused on advancing its two lead product candidates into late-stage trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.